Strong Revenue Growth in 2025 Interim Results
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) recently shared its interim results for the first half of 2025, indicating a remarkable performance for the company. The revenue climbed significantly, achieving a 31.7% increase year-over-year (YoY) to reach RMB 482 million. This growth was accompanied by an impressive surge in net profit, which exceeded RMB 121 million, marking a 76.0% rise and resulting in a net profit margin of 25.1%.
Steady Performance Across Core Businesses
Throughout the initial half of 2025, Zylox-Tonbridge showcased solid performance in its main business areas, particularly in neurovascular and peripheral vascular interventions. Revenue from neurovascular products amounted to RMB 304 million, reflecting a 25.0% increase YoY, while peripheral vascular products brought in RMB 176 million, a substantial YoY rise of 46.2%. This robust performance is indicative of the company's commitment to lean operations, as evidenced by a decrease in combined R&D, selling, and administrative expenses as a percentage of revenue by 7 percentage points compared to the previous year.
International Business Growth
The international segment of Zylox-Tonbridge demonstrated impressive growth in the first half of 2025, with revenue reaching RMB 15.72 million. By the end of June, the company had successfully commercialized 22 products across 27 countries and regions, with over 31 products still under registration in 23 markets. This impressive global network now spans 52 countries, facilitated by partnerships with over 60 local distributors. As the company ramps up overseas commercialization, it becomes an increasingly significant driver of revenue growth.
Innovative Portfolio Fuels Market Penetration
Zylox-Tonbridge harnessed its diverse and high-quality product portfolio along with an efficient commercial team to propel strong sales growth in the first half of the year. Many of the Value-based Procurement (VBP) selected products found renewed success in a stable procurement environment, thereby supporting continued market penetration and share growth.
The sales trajectory for several flagship products, such as the SilverSnake Intermediate Catheter Series, neurovascular guidewires, and the Kylin Flow Diverter, has shown considerable improvement, reflecting increased market penetration. Notably, the Phoenix Coil System has secured renewal under the Jiangsu provincial procurement program, showcasing the effectiveness of the company's strategic approach.
Advancing Product Development
By the period's close, Zylox-Tonbridge expanded its network to encompass over 3,000 hospitals, facilitating the use of its products in more than a million procedures, which underscores the company's commitment to providing high-quality and cost-effective treatments worldwide. Simultaneously, the company drives forward with innovative solutions to address clinical needs. In the first half of the year, both the ZYLOX Eagle Aspiration System and the TONBRIDGE Shunfeng Balloon Vascular Closure Device achieved regulatory approval, further enhancing the product portfolio.
Looking ahead, Zylox-Tonbridge anticipates regulatory approvals for a large-lumen thrombus aspiration catheter, a self-expandable intracranial stent, and an OCT-guided peripheral atherectomy catheter series, which will expand the treatment options in neurovascular and peripheral interventions.
Global Expansion Through Strategic Initiatives
In the first half of 2025, Zylox-Tonbridge intensified investments in international R&D, regulatory registration, and commercialization, propelling its global expansion efforts. The company's products are now present in seven of the top ten medical device markets globally, including notable regions such as France and Germany. Emerging markets like Brazil, India, and South Africa are also experiencing significant growth, presenting new avenues for expansion in the international market.
As a highlight, the ZYLOX Unicorn Vascular Closure System received regulatory approval in Indonesia, marking a significant milestone as the company's first approval in Southeast Asia. Additionally, the ZYLOX Phoenix Peripheral Fibered Detachable Coil Occlusion System gained approval in Ecuador, enhancing the company's presence in South America. The firm continues to participate actively in leading conferences, such as LINC 2025, to strengthen brand recognition throughout Europe and beyond.
Commitment to Innovation and Quality
Zylox-Tonbridge remains steadfast in its mission, "Innovation for Quality Life," as it strives to solidify its position within the China market and bolster international growth. With a focus on real clinical value through differentiated innovation, the company aims to foster long-term sustainable growth while contributing to innovations within global healthcare.
Frequently Asked Questions
What were Zylox-Tonbridge's revenue figures for 2025?
The company reported a revenue increase of 31.7% YoY, reaching RMB 482 million.
How much did the net profit increase?
Zylox-Tonbridge's net profit surged by 76.0% to exceed RMB 121 million.
What are the key product categories driving growth?
The core areas of growth include neurovascular and peripheral vascular interventions.
Which markets is Zylox-Tonbridge expanding into?
The company is targeting both established and emerging markets, including regions like Europe, Brazil, India, and South Africa.
What is Zylox-Tonbridge's mission?
The company's mission is "Innovation for Quality Life," focusing on delivering innovative healthcare solutions.
